RxDoctor Payments Data

Doris Cardenas, MD

Neurology · Mission Hills, CANPI 1144384116

Payments from drug & device makers

$986in general payments, 2019–2025

Across 55 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$542
  • Medtronic$124
  • GE HealthCare$113
  • Amgen$48
  • EMD Serono, Inc.$46
  • UCB, Inc.$33
  • plus $80 from 4 others

What the payments were for

  • Food & beverage$64265%
  • Education$34435%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.37$542
Medtronic3$124
GE HealthCare4$113
Amgen(2 entities)2$48
EMD Serono, Inc.3$46
UCB, Inc.2$33
GSK1$25
AbbVie1$24
Sanofi1$18
AstraZeneca1$14

How this compares

$986 in reported general payments places this provider in the 45th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$93,427
Medicare patients
281
Services billed
4,159

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4641$483,495
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5022$240,785
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5012$155,747
CopaxoneGlatiramer Acetate27$147,654
Avonex Pen (4 Pack)Interferon Beta-1a14$113,548
AustedoDeutetrabenazine19$112,599
NuplazidPimavanserin Tartrate12$67,033
Aimovig AutoinjectorErenumab-Aooe45$65,304
GlatopaGlatiramer Acetate13$45,894
Nurtec OdtRimegepant Sulfate34$44,674
QuliptaAtogepant21$34,496
AptiomEslicarbazepine Acetate28$31,065
Memantine Hcl516$24,978
NourianzIstradefylline13$23,425
Gabapentin707$18,672

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone, Austedo$542$260,25346 claims
AbbVieQulipta$24$34,49621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,996 neurology providers in California.

Other neurology in Mission Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →